Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
about
The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in TherapyThe Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusCardiac toxicity of trastuzumab in elderly patients with breast cancerContralateral prophylactic mastectomy: current perspectivesNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialInfracentimetric HER-2 positive breast tumours-review of the literatureTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewHow Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast CancerClinical application of circulating tumor cells in breast cancer: overview of the current interventional trialsExpert perspectives on biosimilar monoclonal antibodies in breast cancerAdjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Molecular subtypes and imaging phenotypes of breast cancer.The genomics and therapeutics of HER2-positive gastric cancer-from trastuzumab and beyondPrioritizing therapeutic targets using patient-derived xenograft modelsSystemic targeted therapy for her2-positive early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineBreast cancer subtypes and previously established genetic risk factors: a bayesian approachA Network-Based Target Overlap Score for Characterizing Drug Combinations: High Correlation with Cancer Clinical Trial ResultsLong-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer.Ultrasound-stimulated drug delivery for treatment of residual disease after incomplete resection of head and neck cancer.Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialPredicting breast tumor response to neoadjuvant chemotherapy with diffuse optical spectroscopic tomography prior to treatmentPertuzumab and breast cancer: another piece in the anti-HER2 puzzle.Severe thrombocytopenia after trastuzumab retreatment: a case report.Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationA comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer.Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patientsPertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations.Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patientOutcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer.Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with TrastuzumabRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsAdjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclinesFinal report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patientsFirst do no harm: population-based study shows non-evidence-based trastuzumab prescription may harm elderly women with breast cancer.
P2860
Q21284978-1CD9660F-1205-4585-A24D-E94D9DE1F665Q26740184-FF2A71C8-94C7-440E-9F62-492D8EE6CB8CQ26741182-A97B02EC-E129-46C9-9F4F-BD8B5D1F5F93Q26744320-C4672E91-A919-44E3-9074-A2241F1CAD29Q26769884-849972AB-5E27-4C88-96B2-7D5972877B6BQ26774597-2012EFDD-C919-4D92-BEDE-A779C0C61E1CQ26777733-C009952D-1743-4AEF-8A19-60EEBF77FA87Q26824542-87918DEA-E088-463B-B64C-FE0871C0ADC5Q26827936-77F28CD4-F1AC-41D2-AEE3-0C20C5B1472FQ26865410-77924C3D-FB1B-410A-ACCA-DA8CE03EE319Q27025860-32E40FC9-7FA5-4EE6-9EF9-FF766A837926Q27853035-CFBFD7D5-E79E-42A8-BF72-A5661D5B68E9Q28069885-36F161B8-CD56-419A-981C-4F2A950DFCC3Q28078788-706476CF-C4B4-473B-99A8-BC84A7B8CC9CQ28083993-DC3119EA-A0C7-483D-8FCE-05B63B08F2B4Q28260063-8F904F4D-AE88-43C8-B5D4-FEE2034E0A31Q28397311-E6BC8787-99F4-4676-8098-7B539007F2F7Q28547962-1E60DD1A-EF1E-4132-BBCA-063E773F0B57Q30371966-171DE797-DB1F-4E1A-9452-A2759B9DCCA9Q30415659-969857FF-B4CF-469E-B7D3-6AA98C13CE7CQ30537414-CD9C9247-F9B0-4CFA-B707-56EA1C10F295Q30858109-9F835454-AFDC-4901-982D-A9EAFAE08689Q33364587-5BB04EF3-2A76-4698-9C74-E965C6CFDDFBQ33410733-E9E67D70-5D3F-4FFC-BFBA-B08C566A426DQ33411110-BAF0CC01-A1B6-4ED5-97AB-C0C2BB954F06Q33605906-1CB692E8-8D92-4132-B90C-5CD4356D5A23Q33629947-204A9012-23E9-41CB-BC1B-352AFFE9298CQ33644305-84F321A3-0F58-4514-BF67-E1CF44D8B67CQ33680109-6CE35EC1-5C5A-49EA-95A9-F2DC2A2CB1C0Q33688726-64BFBCEB-F3F3-4F34-80F0-FB56E3BFFACCQ33728102-8B5B67C2-BF59-4478-AB5F-527054F8D2BAQ33824842-ADFE4CA3-F8A5-4DA2-A2C6-958C0D87E008Q33831903-2DEE0C65-38AC-4B67-836E-2FB257D989C3Q33843810-AF6E69A6-E1DD-4B66-A179-45137E4013A4Q33862786-3F7FEBA5-3C9C-4135-AA4F-11FE41C72778Q34020878-3DFF129A-F99D-4D75-B280-5CC29B702A30Q34023704-A0A6D743-7C15-458E-BB86-BB5BB68E7F5FQ34023749-0BF93585-A9A8-4952-AE23-F53375164E79Q34083121-8526CC1E-DA09-4E93-BBB9-EB1E08AEB2B5Q34104204-F3D167C0-8C00-456D-8104-42F18690A6B5
P2860
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@ast
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@en
type
label
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@ast
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@en
prefLabel
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@ast
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@en
P2093
P2860
P356
P1476
Four-year follow-up of trastuz ...... om NCCTG N9831 and NSABP B-31.
@en
P2093
Charles E Geyer
Edith A Perez
Edward H Romond
Eleftherios P Mamounas
Jong-Hyeon Jeong
Nancy E Davidson
Norman Wolmark
Peter A Kaufman
Silvana Martino
Vera J Suman
P2860
P304
P356
10.1200/JCO.2011.35.0868
P407
P577
2011-07-18T00:00:00Z